Adenocarcinoma of the Prostate, Stage IV Prostate Cancer
Conditions
Keywords
prostate Cancer, adenocarcinoma of the prostate, stage IV prostate cancer, newly diagnosed stage IV prostate cancer
Brief summary
This phase II trial is studying how well giving gossypol together with androgen ablation therapy works in treating patients with newly diagnosed metastatic prostate cancer. Gossypol may stop the growth of tumor cells by blocking blood flow to the tumor. Androgens can cause the growth of prostate tumor cells. Luteinizing hormone-releasing hormone agonists and drugs, such as bicalutamide, may lessen the amount of androgens made by the body. Giving gossypol together with androgen ablation therapy may be an effective treatment for prostate cancer
Detailed description
PRIMARY OBJECTIVE: I. To determine the percentage of patients with newly diagnosed metastatic prostate cancer who demonstrate undetectable prostate-specific antigen (PSA) (\< 0.2 ng/mL) at 7 months when treated with R-(-)-gossypol (AT-101) and androgen ablation therapy. SECONDARY OBJECTIVES: I. To determine the safety of this regimen in these patients. II. To determine the percentage of patients with PSA \>= 4.0 ng/mL, overall PSA \< 4.0 ng/mL, and a PSA \>= 0.2 ng/mL but \< 4.0 ng/mL during the first 7 months of therapy. OUTLINE: Patients receive R-(-)-gossypol orally (PO) once daily (QD) on days 1-21. Treatment repeats every 28 weeks for 8 courses in the absence of disease progression or unacceptable toxicity. Patients may receive bicalutamide PO QD beginning 6 weeks before the initiation of R-(-)-gossypol and continuing after completion of treatment, at the discretion of the treating physician.
Interventions
DRUGAT-101
AT101 will be administered orally 20 mg/day for 21 days of a 28 day cycle.
DRUGBicalutamide
Daily bicalutamide 50 mg po is encouraged for the first month of LHRH agonist therapy to prevent a flare. Continued bicalutamide use is optional. Bicalutamide will be administered orally at a dose of 50 mg po daily, Day 1 to 28 of each cycle.
OTHERLHRH agent
An LHRH agonist(Leuprolide Acetate or Goserelin)can be administered at standard dosing appropriate to the agent used.
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically proven adenocarcinoma of the prostate with clinical stage D2 disease defined by soft tissue or bony metastasis. * Patients must have elevated PSA ≥ 5 ng/ml within 12 weeks prior to registration. Androgen ablation therapy, which must include an LHRH agonist, will begin 6 weeks prior to initiation of AT101. * Patients are allowed prior local therapy with radiation or surgery. Patients must not have received more than 12 months of androgen ablation therapy or antiandrogen therapy in the adjuvant/neoadjuvant setting and no prior androgen ablation therapy for metastatic disease, beyond the six week induction period prior to initiation of AT101. Patients with prior adjuvant/neoadjuvant androgen ablation therapy must have completed such therapy at least 12 months prior. * Must be 18 years old or older. * Life expectancy of greater than 6 months. * ECOG performance status ≤ 2. * Patients must have normal organ and marrow function as defined below: * leukocytes ≥ 3,000/mcL * absolute neutrophil count ≥ 1,500/mcL * platelets ≥ 100,000/mcL * total bilirubin within normal institutional limits * AST(SGOT)/ALT(SGPT) ≤ 2.5 X institutional upper limit of normal * creatinine within normal institutional limits OR * creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal * There must be no plans to receive concomitant chemotherapy or radiation therapy during the study period. Baseline and on study PSA values must be obtained from the same reference laboratory. * The effects of AT101 on the developing human fetus at the recommended therapeutic dose are unknown. For this reason men and/or their partners must agree to use adequate contraception, (including hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation.
Exclusion criteria
* Patients who have had radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier. * Patients may not be receiving any other investigational agents. * Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to AT101 or other agents used in the study. * Patients with bilateral orchiectomy are not eligible. * Patients presenting with acute cord compression are not eligible. * History of bowel obstruction or GI dismotility disorder. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Any condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease) that impairs their ability to swallow and retain AT-101 tablets. * Requirement for routine use of hematopoietic growth factors (including granulocyte colony stimulating factor, granulocyte macrophage colony stimulating factor, or interleukin-11) or platelet transfusions to maintain absolute neutrophil counts or platelets counts above the required thresholds for study entry. * HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with AT-101.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of Patients With Undetectable Prostate-specific Antigen (PSA) (< 0.2 ng/mL) at End of 7 Cycles | 3 years |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of Patients With PSA ≥ 0.2 ng/mL But < 4.0 ng/mL | 3 years |
| Percentage of Patients With Overall PSA < 4.0 ng/mL | 3 years |
Countries
United States
Participant flow
Recruitment details
Patients were recruited from April 2008 through July 2010, from four academic medical centers.
Pre-assignment details
There are no pre-assignment requirements.
Participants by arm
| Arm | Count |
|---|---|
| AT101 (R-(-)-Gossypol Acetic Acid) | 55 |
| Total | 55 |
Baseline characteristics
| Characteristic | AT101 (R-(-)-Gossypol Acetic Acid) |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 23 Participants |
| Age, Categorical Between 18 and 65 years | 32 Participants |
| Age, Continuous | 61.5 Years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 55 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Gleason Score Gleason Score 10 | 3 participants |
| Gleason Score Gleason Score 6 | 1 participants |
| Gleason Score Gleason Score 7 | 13 participants |
| Gleason Score Gleason Score 8 | 12 participants |
| Gleason Score Gleason Score 9 | 24 participants |
| Gleason Score Not assessed | 2 participants |
| Metastatic disease Bone/node metastases | 52 participants |
| Metastatic disease Visceral metastases | 3 participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 6 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 49 Participants |
| Region of Enrollment United States | 55 participants |
| Sex: Female, Male Female | 0 Participants |
| Sex: Female, Male Male | 55 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 55 / 55 |
| serious Total, serious adverse events | 13 / 55 |
Outcome results
Primary
Percentage of Patients With Undetectable Prostate-specific Antigen (PSA) (< 0.2 ng/mL) at End of 7 Cycles
Time frame: 3 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| AT101 (R-(-)-Gossypol Acetic Acid) | Percentage of Patients With Undetectable Prostate-specific Antigen (PSA) (< 0.2 ng/mL) at End of 7 Cycles | 22 percentage of participants |
Secondary
Percentage of Patients With Overall PSA < 4.0 ng/mL
Time frame: 3 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| AT101 (R-(-)-Gossypol Acetic Acid) | Percentage of Patients With Overall PSA < 4.0 ng/mL | 60 percentage of participants |
Secondary
Percentage of Patients With PSA ≥ 0.2 ng/mL But < 4.0 ng/mL
Time frame: 3 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| AT101 (R-(-)-Gossypol Acetic Acid) | Percentage of Patients With PSA ≥ 0.2 ng/mL But < 4.0 ng/mL | 18 percentage of participants |